Organon & Co | OGN - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Celltrion KRW 11.84B 1.34B 2026-03
Cspc Pharmaceutical CNY 505.59M 706M 2025-12
Dianthus Therapeutics USD -40.83M 23.6M 2026-03
Divis Laboratories Ltd INR 9.63B 1.09B 2026-03
Gilead Sciences USD 2.08B 1.56B 2025-12
Glaxosmithkline GBP 2.14B 312M 2026-03
Kangmei Pharma CNY -14.01M 16.08M 2026-03
Knight Therapeutics CAD -1.92M 13.69M 2025-09
Laboratorios Farma EUR 26.78M 94.77M 2025-06
Medical Developments International AUD -149K 466K 2025-06
Merck USD 3.42B 3.32B 2025-12
Neuren Pharmaceuticals AUD 9.86M 161.24M 2025-06
Novartis USD 3.84B 1.33B 2026-03
Organigram Holdings CAD -921K 40.8M 2026-03
Organon & Co USD 213M 361M 2026-03
Pharma Mar EUR 1.6M 38.6M 2026-03
Qiagen NV USD 109.17M 25.56M 2025-12
Sartorius EUR 157.8M 76.1M 2026-03
Tilray USD -39.96M 39.19M 2025-09
Zealand Pharma A/S -406.5M 39.77M 2025-12